Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine

Nature Medicine

Volumn 5, Issue 6, 1999, Pages 643-650

  Cafaro, Aurelio ^a   Caputo, Antonella ^b   Fracasso, Claudio ^a   Maggiorella, Maria T ^a   Goletti, Delia ^a   Baroncelli, Silvia ^a   Pace, Monica ^a   Sernicola, Leonardo ^a   Koanga Mogtomo, Martin L ^a   Betti, Monica ^b   Borsetti, Alessandra ^a   Belli, Roberto ^a   Åkerblom, Lennart ^c   Corrias, Franco ^a   Buttò, Stefano ^a   Heeney, Jonathan ^d   Verani, Paola ^a   Titti, Fausto ^a   Ensoli, Barbara ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c NATIONAL VETERINARY INSTITUTE   (Sweden)

^d BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; TRANSACTIVATOR PROTEIN;

ADOLESCENT; ANIMAL CELL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNIZATION; INTRADERMAL DRUG ADMINISTRATION; MONKEY; NONHUMAN; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE SUBPOPULATION; VIRUS REPLICATION;

AIDS VACCINES; ANIMALS; ANTIBODY FORMATION; CD4-POSITIVE T-LYMPHOCYTES; GENE PRODUCTS, TAT; HIV-1; IMMUNITY, CELLULAR; MACACA FASCICULARIS; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VACCINATION; VIRUS REPLICATION;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA FASCICULARIS; SIMIAE; SIMIAN IMMUNODEFICIENCY VIRUS; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0033026062     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/9488     Document Type: Article

References (59)

1. Almond, N.M., & Heeney, J.L. AIDS vaccine development in primate models. AIDS 12, 133-140 (1998).
2. Burton, D.R. & Moore, J.P. Why do not have an HIV vaccine and how can we make one? Nature Med. 4, 495-498 (1998).
3. Berman, P.W. et al. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature 345, 622-625 (1990).
4. Girard, M. et al. Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 88, 542-546 (1991).
5. Stott, E.J. et al. Evaluation of a candidate human immunodeficiency virus type 1 (HIV-1) vaccine in macaques: effects of vaccination with HIV-1 gp120 on subsequent challenge with heterologous simian immunodeficiency virus-HIV-1 virus. J. Gen. Virol. 79, 423-432 (1998).
6. Kestler, H.D. et al. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 65, 651-662 (1991).
7. Daniel, M.D., Kirchhoff, F., Czajak, S.C., Sehgal, P.K., & Desrosiers, R.C. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258, 1938-1941 (1992).
8. Titti, F. et al. Live-attenuated simian immunodeficiency virus prevents super-infection by cloned SIVmac251 in Cynomolgus monkeys. J. Gen. Virol. 78, 2529-2539 (1997).
9. Whatmore, A.M. et al. Repair and evolution of nef in vivo modulates Simian Immunodeficiency Virus virulence. J. Virol. 69, 5117-5123 (1995).
10. Baba, T.W. et al., Pathogenicity of live attenuated SIV after mucosal infection of neonatal macaques. Science 267, 1820-1825 (1995).
11. Ezzell, C. The monkey's got AIDS: what now for live AIDS vaccine? J. NIH Res. 9, 21-22 (1997).
12. Arya, S.K., Guo, C., Josephs, S.F. & Wong-Staal, F. The trans-activator gene of human T-lymphotropic virus type III (HTLV-III). Science 229, 69-73 (1985).
13. Fisher, A.G. et al. The trans-activator gene of HTLV-III is essential for virus replication. Nature 320, 367-371 (1986).
14. Chang, H.-K., Gallo, R.C. & Ensoli, B. Regulation of cellular gene expression and function by the human immunodeficiency virus type 1 Tat protein. J. Biomed. Sci. 2, 189-202 (1995).
15. Ensoli, B. et al. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature 345, 84-87 (1990).
16. Ensoli, B. et al. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J. Virol. 67, 277-287 (1993).
17. Chang, H.C., Samaniego, F., Nair, B.C., Buonaguro, L. & Ensoli, B. HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. AIDS 11, 1421-1431 (1997).
18. Westendorp, M.O. et al. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp 120. Nature 275, 497-500 (1995).
19. Frankel, A.D. & Pabo, CO. Cellular uptake of the Tat protein from human immunodeficiency virus. Cell 55, 1189-1193 (1988).
20. Barillari, G. et al. Effect of cytokines from activated immune cells on vascular cell growth and HIV-1 gene expression. Implications for AIDS-Kaposi's sarcoma pathogenesis. J. Immunol. 149, 3727-3734 (1992).
21. Huang, L., Bosh, I., Hofmann, W., Sodroski, J. & Pardee, A.B. Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strains. J. Virol. 72, 8952-8960 (1998).
22. Li, C.J. et al. Tat protein induces self-perpetuating permissivity for productive HIV-1 infection. Proc. Natl. Acad. Sci. USA 94, 8116-8120 (1997).
23. Viscidi, R.P., Mayur, K., Lederman, H.M. & Frankel, A.D. Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1. Science 246, 1606-1608 (1989).
24. Barillari, G., Gendelman, R., Gallo, R.C. & Ensoli, B. The Tat protein of human immunodeficiency virus type-1, a growth factor for AIDS Kaposi's sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence. Proc. Natl. Acad. Sci. USA 90, 7941-7945 (1993).
25. Subramanyam, M., Gutheil, W.G., Bachovchin, W.W. & Huber, B.T. Mechanism of HIV-1 Tat induced inhibition of antigen-specific T cell responsiveness. J. Immunol. 150, 2544-2553 (1993).
26. Zagury, J.F. et al. Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS. Proc. Natl. Acad. Sci. USA 95, 3851-3856 (1998).
27. Ensoli, B. et al. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature 371, 674-680 (1994).
28. Li C.J., Friedman D.J., Wang C., Metelev V. & Pardee A.B. Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein. Science 268, 429-431 (1995).
29. Zauli, G. et al. Pleiotropic effects of immobilized versus soluble recombinant HIV-1 Tat protein on CD3-mediated activation, induction of apoptosis, and HIV-1 long terminal repeat transactivation in purified CD4+ T lymphocytes. J. Immunol. 157, 2216-2224 (1996).
30. Zagury, J.F. et al. Mode of AIDS immunopathogenesis based on the HIV-1 gp120 and Tat-induced dysregulation of uninfected immune cells. Cell Pharmacol. 3, 123-128 (1996).
31. Reiss, P. et al. Speed of progression to AIDS and degree of antibody response to accessory gene products of HIV-1. J. Med. Virol. 30, 163-168 (1990).
32. Rodman, T.C., To, S.E., Hashish, H. & Manchester, K. Epitopes for natural antibodies of human immunodeficiency virus (HIV)-negative (normal) and HIV-positive sera are coincident with two key functional sequences of HIV Tat protein. Proc Natl Acad Sci. USA 90, 7719-7723 (1993).
33. Re, C. et al. Effect of antibody to HIV-1 Tat protein on viral replication in vitro and progression of HIV-1 disease in vivo. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 10, 408-416 (1995).
34. Zagury, J.F. et al. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine. J. Hum. Virol. 4, 282-292 (1998).
35. Venet, A., Bourgault, I., Aubertin, A.M., Kiény, M.P. & Levy, J.P. Cytotoxic T lymphocyte response against multiple simian immunodeficiency virus (SIV) proteins in SIV-infected macaques. J. Immunol. 148, 2899-2908 (1992).
36. Van Baalen, C.A. et al. HIV-1 Rev and Tat specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. J. Gen. Virol. 78, 1913-1918 (1997).
37. Froebel, K.S. et al. Cytotoxic T lymphocyte activity in children infected with HIV. AIDS Res. Hum. Retrovir. 2, 83-88 (1994).
38. Fawell, S. et al. Tat-mediated delivery of heterologous proteins into cells. Proc. Natl. Acad. Sci. USA 91, 664-668 (1994).
39. Kim, D.T. et al. Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide. J. Immunol. 159, 1666-1668 (1997).
40. Human Retroviruses and AIDS 1995. A Compilation and Analysis of Nucleic Acids and Amino Acid Sequences (eds. Korber, B. et al.) II-A-55, 56 (Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, New Mexico, 1995).
41. Goldstein, G. HIV-1 Tat protein as a potential AIDS vaccine. Nature Med. 1, 960-964 (1996).
42. Davis, D. et al. A recombinant prime, peptide boost vaccination strategy can focus the immune response on to more than one epitope even though these may not be immunodominant in the complex immunogen. Vaccine 15, 1661-1669 (1997).
43. Perez, C. et al. A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. Cell 63, 251-258 (1990).
44. Jassoy, C. et al. Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes release gamma interferon, tumor necrosis factor alpha (TNFα), and TNF-β when they encounter their target antigens. J. Virol. 67, 2844-2852 (1993).
45. Ratner, A. & Clark, W.R. Role of TNF-α in CD8+ cytotoxic T lymphocyte-mediated lysis. J. Immunol. 150, 4303-4314 (1993).
46. Ando, K. et al. Perform, Fas/Fas ligand, and TNF-α pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL. J. Immunol. 158, 5283-5291 (1997).
47. Reimann, K.A. et al. A chimeric simian/human immunodeficiency virus expressing a primary patients human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J. Virol. 70, 6922-6928 (1996).
48. Lamhamedi-Cherradi, S. et al. Qualitative and quantitative analysis of human cytotoxic T-lymphocyte responses to HIV-1 proteins. AIDS 6, 1249-1258 (1992).
49. Rinaldo, C.R. et al. Anti-HIV type 1 cytotoxic T lymphocyte effector activity and disease progression in the first 8 years of HIV type 1 infection of homosexual men. AIDS Res. Hum. Retrovir. 11, 481-489 (1995).
50. Ogg, G.S. et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 279, 2103-2106 (1998).
51. Buonaguro, L. et al. Heteroduplex mobility assay and phylogenetic analysis of V3 region sequences of human immunodeficiency virus type 1 isolates from Gulu, northern Uganda. The Italian-Ugandan Cooperation AIDS Program. J. Virol. 69, 7971-7981 (1995).
52. Calarota, S. et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 351, 1320-1325 (1998).
53. Gringeri, A. et al. Safety and Immunogenicity of HIV-1 Tat Toxoid in Immunocompromised HIV-1 Infected Patients. J. Hum. Virol. 1, 293-298 (1998).
54. Caselli, E. et al. DNA Immunization with HIV-1 tat Mutated in the Transactivation Domain Induces Humoral and Cellular Immune Responses against Wild-Type TAT. J. Immunol. (in the press).
55. Chen, Z.W. et al. Cytotoxic T lymphocytes do not appear to select for mutations in an immunodominant epitope of simian immunodeficiency J. Immunol. 149, 4060-4066 (1992).
56. Lövgren, J. & Blomberg, K. Simultaneous measurement of NK cell cytotoxicity against two target cell lines labelled with fluorescent lanthanide chelates J. Immunol. Methods 173, 119-125 (1994).
57. Sodora, D.L., Lee, F., Dailey, P.J. & Marx, P.A. A genetic and viral load analysis of the simian immunodeficiency virus during the acute phase in macaques inoculated by the vaginal route. AIDS Res. Hum. Retroviruses 14, 171-181 (1998).
58. Saiki, R.K. et al. Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science 230, 1350-1354 (1985).
59. Fiore, J.R. et al. Pokeweed mitogen-stimulated peripheral blood mononuclear cells from at-risk seronegative subjects produce in vitro HIV-1-specific antibodies. AIDS 5, 1034-1036 (1991).